Client: Actelion Pharmaceuticals Australia

Actelion is a global leader in the science and medicine of Pulmonary Arterial Hypertension having launched the first endothelin receptor antagonist (ERA) bostentan, in 2001. Since then Actelion has development a portfolio of PAH treatments including macitentan and a generic epoprostenal with improved thermal stability.

When Actelion wanted to publish clinical case studies on bosentan, Leo Creative named and created PAH Clinic – a corporate (rather than product) branded, journal-like publication to reinforce Actelion’s leadership in PAH. The publication has proved to be one of Actelion’s most useful in-field resources – working across their PAH product portfolio and providing a vehicle for engaging with and promoting Key Opinion Leaders.